02073nas a2200277   4500000000100000008004100001260001300042653001200055653002600067653001600093653004400109653001100153653003200164653003100196653002200227653003800249100001200287700001700299700001700316700001800333245008700351300001100438490000700449520132500456022001401781       2013                            d  c2013 Aug10aAnimals10aAntitubercular Agents10aClofazimine10aExtensively Drug-Resistant Tuberculosis10aHumans10aMicrobial Sensitivity Tests10aMycobacterium tuberculosis10aTreatment Outcome10aTuberculosis, Multidrug-Resistant1 aGopal M1 aPadayatchi N1 aMetcalfe J Z1 aO'Donnell M R00aSystematic review of clofazimine for the treatment of drug-resistant tuberculosis.  a1001-70 v173 a<p>The increased incidence of drug-resistant tuberculosis has created an urgent necessity for the development of new and effective anti-tuberculosis drugs and for alternative therapeutic regimens. Clofazimine (CFZ) is a fat-soluble riminophenazine dye used in the treatment of leprosy worldwide. CFZ has also been used as a Group 5 drug in the treatment of tuberculosis (TB). A large cohort study from Bangladesh published in 2010 described a treatment regimen for multidrug-resistant tuberculosis (MDR-TB) including CFZ as being highly effective against MDR-TB. We searched multiple databases for studies published through February 2012 that reported use of CFZ in MDR- and extensively drug-resistant TB (XDR-TB) treatment regimens. We identified nine observational studies (6 MDR-TB and 3 XDR-TB) including patients with drug-resistant TB treated with CFZ. Overall, 65% (95% confidence interval [95%CI] 54-76) of the patients experienced favorable outcomes, defined as either cure or treatment completion. Using random effects meta-analysis, 65% (95%CI 52-79) of those with MDR-TB and 66% (95%CI 42-89) of those with XDR-TB experienced favorable treatment outcomes. High-quality prospective cohort studies and clinical trials examining the effect of CFZ as part of drug-resistant TB treatment regimens are needed. </p>  a1815-7920